Medical News
Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.
Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy
Despite advances in the therapy of bronchial asthma, a portion of patients still do not achieve the desired control of the disease. The introduction of biological treatment marked a significant…
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis…
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the work presented below discuss the significance of prophylactic administration of factor VIII coagulation…
Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia…
Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease
Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular (CV) events and higher mortality. However, this association has not been thoroughly investigated in…
Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is…
Benefits of Enoxaparin Prophylaxis in Pregnancy and Postpartum
Study results suggest that the use of low molecular weight heparins during pregnancy could lead to better outcomes for women with thrombophilia and recurrent miscarriages. A group of authors from…
Impact of Combined Oral Contraceptives on Body Weight
A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and…
Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients
Authors of a Franco-Spanish study propose using the monocyte distribution width along with leukocyte count as a screening test to refine the early diagnosis of sepsis in intensive care unit (ICU)…
Prevention of Skeletal Events in the Therapy of Patients with Advanced Prostate Cancer
Prostate cancer most commonly forms metastases in the bones. In patients with this advanced disease, skeletal events occur, negatively affecting their quality of life. Zoledronic acid and denosumab…
The Immune System in the Pathophysiology of ITP
From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.
Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia
Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years.…
Anticoagulation Therapy in Patients on ECMO During the COVID-19 Pandemic
In the past 2 years, the use of extracorporeal membrane oxygenation (ECMO) in intensive care units (ICU) has increased in connection with the treatment of severe COVID-19 pneumonia. Dr. Pilar Marcos…
Can Erdostein Help in Treating Infections Related to Biofilm Formation?
One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a…